Humalog® U200, a double strength formulation of insulin lispro, has recently been added to the Pharmaceutical Benefits Scheme (PBS). This ultra-short-acting insulin is indicated for the management of type 1 and type 2 diabetes mellitus.

The range of products containing insulin lispro is shown in Table 1.

Table 1. Insulin lispro products available

Product Insulin Strength Presentation
Humalog® Insulin lispro 100units/mL Vial, cartridge, KwikPen® device
Humalog® U200 Insulin lispro 200units/mL KwikPen® device
Humalog Mix25® Insulin lispro + lispro protamine 100units/mL Cartridge, KwikPen® device
Humalog Mix50® Insulin lispro + lispro protamine 100units/mL Cartridge, KwikPen® device

This new high-strength formulation is only available in the disposable KwikPen® device. The prescribed dose is dialled up in units for both the 200 units/mL and the 100 units/mL KwikPen® device. Therefore, no dose conversion is required when a patient changes to the new strength. To avoid dosing errors, the solution from the pre-filled pen must not be mixed with any other insulin or transferred to any other insulin delivery device. Drawing insulin out of the Humalog U200 KwikPen® and measuring the dose using an insulin needle with unit markings would result in a two-fold dosing error.

Insulin is considered high-strength when the concentration exceeds 100 units/mL. High-strength insulins such as Humalog® U200 and Toujeo® (insulin glargine 300 units/mL) may be beneficial for patients needing high daily doses as lower injection volumes are required. This can reduce the pain of injection and may also limit variability in absorption.


  1. Humalog® U200 (insulin lispro) Australian approved product information. West Ryde: Eli Lilly. Approved November 2015.
  2. Lamos EM, Younk LM, Davis SN. Concentrated insulins: the new basal insulins. Ther Clin Risk Manag. 2016; 12: 389-400.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates